tegafur has been researched along with 4-hydroxybutyric acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K | 1 |
| Fukushima, M; Ishikawa, S; Miyahara, R; Nakagawa, T; Tanaka, F; Wada, H | 1 |
| Emi, Y; Fukui, Y; Kakeji, Y; Maehara, Y; Oki, E; Sumiyoshi, Y | 1 |
3 other study(ies) available for tegafur and 4-hydroxybutyric acid
| Article | Year |
|---|---|
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; Diffusion Chambers, Culture; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Hydroxybutyrates; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Tegafur; Tumor Cells, Cultured; Uracil | 1999 |
UFT inhibits lung metastases in spontaneous metastasis model of lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Humans; Hydroxybutyrates; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Tegafur; Uracil | 2005 |
Pharmacokinetics of gamma-hydroxybutylic acid (GHB) and gamma-butyrolactone (GBL), the anti-angiogenic metabolites of oral fluoropyrimidine UFT, in patients with gastric cancer.
Topics: 4-Butyrolactone; Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Drug Combinations; Female; Humans; Hydroxybutyrates; Male; Middle Aged; Stomach Neoplasms; Tegafur; Uracil | 2007 |